Overview and Future Considerations for the Structure and Features of Patient Engagement in Canada’s Pharmaceutical System Overview and Future Considerations for the Structure and Features of Patient Engagement in Canada’s Pharmaceutical System

Patient engagement across Canada’s pharmaceutical system aims to incorporate patient experiences and needs into decision-making from drug discovery through to post-market activities. Given the current context of pharmaceutical policy changes, it is an opportune time to reflect on patient engagement processes with the goal of creating systematic, coordinated, and meaningful processes. This report identifies current approaches and gaps in patient engagement methods across the pharmaceutical system. Several improvement opportunities to build linkages and trust with patient communities are identified, including the implementation of a system-wide approach for coordinated patient engagement and support, incorporating patient representation in governance, and establishing a national organization that is agnostic of health conditions to foster capacity building, inclusive practices, and evaluation. This is the final report of the Patient Advisor to the Canadian Drug Agency Transition Office (CDATO) made in April 2024.

在加拿大药品体系内，患者参与的宗旨在于将患者的体验与需求融入从药物发现至上市后活动的决策过程中。鉴于当前药品政策变革的背景，反思患者参与流程恰逢其时，旨在构建系统化、协调一致且富有意义的流程。本报告旨在识别药品体系中患者参与方法的现行做法与不足之处。报告提出了数项改善机会，旨在构建与患者群体的联系与信任，包括实施全系统协调患者参与的策略，将患者代表纳入治理结构，以及建立一个不受健康条件限制的国家级组织，以促进能力建设、包容性实践和评估。这是患者顾问向加拿大药品管理局过渡办公室（CDATO）提交的最终报告，提交时间为2024年4月。